Cargando…
1672. Eligibility and Outcomes of Conversion to Oral (PO) Therapy in Patients Hospitalized with Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis
BACKGROUND: Rising rates of fluoroquinolone resistance (FQ-R) and third-generation cephalosporin resistance/extended-spectrum beta-lactamases (ESBL+) have left patients with urinary tract infections (UTI) few oral options. Here, we evaluate the eligibility of hospitalized UTI patients to take PO med...
Autores principales: | Melnick, David, Jain, Akash, Gupta, Vikas, Sulham, Katherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778096/ http://dx.doi.org/10.1093/ofid/ofaa439.1850 |
Ejemplares similares
-
1684. Hospital Costs and Reimbursement in Patients with Resistant Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis
por: Melnick, David, et al.
Publicado: (2020) -
1691. Pre- and Post-Hospitalization Resource Utilization and Costs Associated with Urinary Tract Infection (UTI) in both Commercial and Medicare Populations
por: Melnick, David, et al.
Publicado: (2020) -
1504. Patient Demographics and Comorbidity Profiles Associated with Hospitalized Patients Admitted with Resistant vs. Susceptible Urinary Tract Infections (UTIs): A Multicenter Analysis
por: Bruss, Jon, et al.
Publicado: (2018) -
1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
por: Lodise, Thomas, et al.
Publicado: (2020) -
LB-3. Oral Tebipenem Pivoxil Hydrobromide is Non-inferior to IV Ertapenem in Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) – Results from the Pivotal ADAPT-PO Study
por: Muir, Lori A, et al.
Publicado: (2020)